Akero Therapeutics, Inc.
NASDAQ:AKRO
32.33 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.029 | 0.26 | 0.244 | 0.213 | 0 | 0 | 0 |
| Gross Profit
| -0.029 | -0.26 | -0.244 | -0.213 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 141.798 | 85.284 | 81.759 | 64.916 | 37.046 | 11.882 | 3.486 |
| General & Administrative Expenses
| 30.55 | 29.872 | 19.127 | 15.238 | 8.605 | 1.896 | 1.176 |
| Selling & Marketing Expenses
| -0.029 | 0 | 0 | 0 | 0 | 0 | -0.098 |
| SG&A
| 31.072 | 29.872 | 19.127 | 15.238 | 8.605 | 1.896 | 1.078 |
| Other Expenses
| 0 | 3.862 | 0.109 | 0.947 | 1.896 | -67.936 | 0 |
| Operating Expenses
| 172.869 | 115.156 | 100.886 | 80.154 | 45.651 | 13.778 | 4.564 |
| Operating Income
| -172.87 | -115.156 | -100.886 | -80.154 | -45.651 | -13.778 | -4.564 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 21.111 | 3.123 | 0.109 | 0.947 | 1.896 | -67.936 | 0 |
| Income Before Tax
| -151.759 | -112.033 | -100.777 | -79.207 | -43.755 | -81.714 | -4.564 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -3.123 | -0.041 | -0.017 | 0.024 | -68.097 | -4.979 |
| Net Income
| -151.759 | -108.91 | -100.736 | -79.19 | -43.755 | -81.714 | -4.564 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.89 | -2.79 | -2.89 | -2.52 | -2.9 | -3.85 | -0.16 |
| EPS Diluted
| -2.89 | -2.79 | -2.89 | -2.52 | -2.9 | -3.85 | -0.16 |
| EBITDA
| -172.841 | -111.294 | -100.886 | -80.154 | -45.651 | -81.714 | -4.564 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |